JP2005342336A - 生体吸収性を有する新規材料、その製造方法、及びその用途 - Google Patents
生体吸収性を有する新規材料、その製造方法、及びその用途 Download PDFInfo
- Publication number
- JP2005342336A JP2005342336A JP2004167632A JP2004167632A JP2005342336A JP 2005342336 A JP2005342336 A JP 2005342336A JP 2004167632 A JP2004167632 A JP 2004167632A JP 2004167632 A JP2004167632 A JP 2004167632A JP 2005342336 A JP2005342336 A JP 2005342336A
- Authority
- JP
- Japan
- Prior art keywords
- metal element
- compound
- acid
- differentiation
- proliferation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000463 material Substances 0.000 title claims abstract description 61
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 9
- 229910052751 metal Inorganic materials 0.000 claims abstract description 80
- 239000002184 metal Substances 0.000 claims abstract description 74
- 150000001875 compounds Chemical class 0.000 claims abstract description 31
- 230000004069 differentiation Effects 0.000 claims abstract description 26
- 230000035755 proliferation Effects 0.000 claims abstract description 25
- 230000001737 promoting effect Effects 0.000 claims abstract description 20
- 230000000379 polymerizing effect Effects 0.000 claims abstract description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 39
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 33
- -1 alkoxide compound Chemical class 0.000 claims description 28
- 235000014655 lactic acid Nutrition 0.000 claims description 21
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 19
- 239000004310 lactic acid Substances 0.000 claims description 18
- 229920001577 copolymer Polymers 0.000 claims description 17
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims description 17
- 239000010936 titanium Substances 0.000 claims description 14
- 229910052719 titanium Inorganic materials 0.000 claims description 14
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 11
- 229910052735 hafnium Inorganic materials 0.000 claims description 11
- 229910052725 zinc Inorganic materials 0.000 claims description 11
- 239000011701 zinc Substances 0.000 claims description 11
- VBJZVLUMGGDVMO-UHFFFAOYSA-N hafnium atom Chemical compound [Hf] VBJZVLUMGGDVMO-UHFFFAOYSA-N 0.000 claims description 10
- 229910052742 iron Inorganic materials 0.000 claims description 10
- 229910052715 tantalum Inorganic materials 0.000 claims description 10
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 9
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 claims description 9
- 229910052758 niobium Inorganic materials 0.000 claims description 9
- 239000010955 niobium Substances 0.000 claims description 9
- 229910052726 zirconium Inorganic materials 0.000 claims description 9
- GUCVJGMIXFAOAE-UHFFFAOYSA-N niobium atom Chemical compound [Nb] GUCVJGMIXFAOAE-UHFFFAOYSA-N 0.000 claims description 8
- 229920001059 synthetic polymer Polymers 0.000 claims description 8
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 claims description 8
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 4
- 238000002513 implantation Methods 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- 239000002861 polymer material Substances 0.000 claims 2
- 229920000642 polymer Polymers 0.000 abstract description 19
- 239000003054 catalyst Substances 0.000 abstract description 8
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 abstract description 2
- 238000007142 ring opening reaction Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 34
- 210000001519 tissue Anatomy 0.000 description 25
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 14
- 210000001612 chondrocyte Anatomy 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 8
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229920000747 poly(lactic acid) Polymers 0.000 description 6
- 239000004626 polylactic acid Substances 0.000 description 6
- 230000001172 regenerating effect Effects 0.000 description 6
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 6
- POILWHVDKZOXJZ-ARJAWSKDSA-M (z)-4-oxopent-2-en-2-olate Chemical compound C\C([O-])=C\C(C)=O POILWHVDKZOXJZ-ARJAWSKDSA-M 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 4
- 230000024245 cell differentiation Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 238000007151 ring opening polymerisation reaction Methods 0.000 description 4
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 description 4
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- PDPJQWYGJJBYLF-UHFFFAOYSA-J hafnium tetrachloride Chemical compound Cl[Hf](Cl)(Cl)Cl PDPJQWYGJJBYLF-UHFFFAOYSA-J 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 210000000578 peripheral nerve Anatomy 0.000 description 3
- 239000002685 polymerization catalyst Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229920001897 terpolymer Polymers 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 235000005074 zinc chloride Nutrition 0.000 description 3
- 239000011592 zinc chloride Substances 0.000 description 3
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- REKYPYSUBKSCAT-UHFFFAOYSA-N 3-hydroxypentanoic acid Chemical compound CCC(O)CC(O)=O REKYPYSUBKSCAT-UHFFFAOYSA-N 0.000 description 2
- ALRHLSYJTWAHJZ-UHFFFAOYSA-N 3-hydroxypropionic acid Chemical compound OCCC(O)=O ALRHLSYJTWAHJZ-UHFFFAOYSA-N 0.000 description 2
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 229910021577 Iron(II) chloride Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCKIEQZJEYYRIY-UHFFFAOYSA-N Titanium ion Chemical compound [Ti+4] LCKIEQZJEYYRIY-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- FPCJKVGGYOAWIZ-UHFFFAOYSA-N butan-1-ol;titanium Chemical compound [Ti].CCCCO.CCCCO.CCCCO.CCCCO FPCJKVGGYOAWIZ-UHFFFAOYSA-N 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical compound CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- ZMHZSHHZIKJFIR-UHFFFAOYSA-N octyltin Chemical compound CCCCCCCC[Sn] ZMHZSHHZIKJFIR-UHFFFAOYSA-N 0.000 description 2
- YHBDIEWMOMLKOO-UHFFFAOYSA-I pentachloroniobium Chemical compound Cl[Nb](Cl)(Cl)(Cl)Cl YHBDIEWMOMLKOO-UHFFFAOYSA-I 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920006254 polymer film Polymers 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- OEIMLTQPLAGXMX-UHFFFAOYSA-I tantalum(v) chloride Chemical compound Cl[Ta](Cl)(Cl)(Cl)Cl OEIMLTQPLAGXMX-UHFFFAOYSA-I 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 2
- DUNKXUFBGCUVQW-UHFFFAOYSA-J zirconium tetrachloride Chemical compound Cl[Zr](Cl)(Cl)Cl DUNKXUFBGCUVQW-UHFFFAOYSA-J 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 1
- CYWDDBNPXTUVNN-UHFFFAOYSA-I 2-ethylhexanoate;niobium(5+) Chemical compound [Nb+5].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O CYWDDBNPXTUVNN-UHFFFAOYSA-I 0.000 description 1
- XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 1
- VSKXVGWORBZZDY-UHFFFAOYSA-N 2-hydroxypropanoic acid;oxepan-2-one Chemical compound CC(O)C(O)=O.O=C1CCCCCO1 VSKXVGWORBZZDY-UHFFFAOYSA-N 0.000 description 1
- BGGIUGXMWNKMCP-UHFFFAOYSA-N 2-methylpropan-2-olate;zirconium(4+) Chemical compound CC(C)(C)O[Zr](OC(C)(C)C)(OC(C)(C)C)OC(C)(C)C BGGIUGXMWNKMCP-UHFFFAOYSA-N 0.000 description 1
- HPMGFDVTYHWBAG-UHFFFAOYSA-N 3-hydroxyhexanoic acid Chemical compound CCCC(O)CC(O)=O HPMGFDVTYHWBAG-UHFFFAOYSA-N 0.000 description 1
- 229940006015 4-hydroxybutyric acid Drugs 0.000 description 1
- 206010010149 Complicated fracture Diseases 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002473 artificial blood Substances 0.000 description 1
- 239000012237 artificial material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- UARGAUQGVANXCB-UHFFFAOYSA-N ethanol;zirconium Chemical compound [Zr].CCO.CCO.CCO.CCO UARGAUQGVANXCB-UHFFFAOYSA-N 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- LVXMQJMWYDFZOS-UHFFFAOYSA-N hafnium 1,1,1-trifluoropentane-2,4-dione Chemical compound [Hf].CC(=O)CC(=O)C(F)(F)F LVXMQJMWYDFZOS-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- AQBLLJNPHDIAPN-LNTINUHCSA-K iron(3+);(z)-4-oxopent-2-en-2-olate Chemical compound [Fe+3].C\C([O-])=C\C(C)=O.C\C([O-])=C\C(C)=O.C\C([O-])=C\C(C)=O AQBLLJNPHDIAPN-LNTINUHCSA-K 0.000 description 1
- DLAPQHBZCAAVPQ-UHFFFAOYSA-N iron;pentane-2,4-dione Chemical class [Fe].CC(=O)CC(C)=O DLAPQHBZCAAVPQ-UHFFFAOYSA-N 0.000 description 1
- VQHSOMBJVWLPSR-UHFFFAOYSA-N lactitol Chemical compound OCC(O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O VQHSOMBJVWLPSR-UHFFFAOYSA-N 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- QASMZJKUEABJNR-UHFFFAOYSA-N methanolate;tantalum(5+) Chemical compound [Ta+5].[O-]C.[O-]C.[O-]C.[O-]C.[O-]C QASMZJKUEABJNR-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000012778 molding material Substances 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- MNJTXOYCAGJFQQ-UHFFFAOYSA-N niobium(3+) Chemical compound [Nb+3] MNJTXOYCAGJFQQ-UHFFFAOYSA-N 0.000 description 1
- ZTILUDNICMILKJ-UHFFFAOYSA-N niobium(v) ethoxide Chemical compound CCO[Nb](OCC)(OCC)(OCC)OCC ZTILUDNICMILKJ-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- GYUPBLLGIHQRGT-UHFFFAOYSA-N pentane-2,4-dione;titanium Chemical compound [Ti].CC(=O)CC(C)=O GYUPBLLGIHQRGT-UHFFFAOYSA-N 0.000 description 1
- WATYAKBWIQTPDE-UHFFFAOYSA-N pentane-2,4-dione;zinc Chemical class [Zn].CC(=O)CC(C)=O WATYAKBWIQTPDE-UHFFFAOYSA-N 0.000 description 1
- SGNLDVYVSFANHW-UHFFFAOYSA-N pentane-2,4-dione;zirconium Chemical class [Zr].CC(=O)CC(C)=O SGNLDVYVSFANHW-UHFFFAOYSA-N 0.000 description 1
- 229920000111 poly(butyric acid) Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- HSXKFDGTKKAEHL-UHFFFAOYSA-N tantalum(v) ethoxide Chemical compound [Ta+5].CC[O-].CC[O-].CC[O-].CC[O-].CC[O-] HSXKFDGTKKAEHL-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- PKJOUIVGCFHFTK-UHFFFAOYSA-L zinc;hexanoate Chemical compound [Zn+2].CCCCCC([O-])=O.CCCCCC([O-])=O PKJOUIVGCFHFTK-UHFFFAOYSA-L 0.000 description 1
- NHXVNEDMKGDNPR-UHFFFAOYSA-N zinc;pentane-2,4-dione Chemical compound [Zn+2].CC(=O)[CH-]C(C)=O.CC(=O)[CH-]C(C)=O NHXVNEDMKGDNPR-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
- Surgical Instruments (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Polyesters Or Polycarbonates (AREA)
Abstract
【解決手段】少なくとも一種のラクチド系化合物を、触媒量の生体細胞の増殖・分化の機能促進作用を示す金属元素又はその化合物の存在下で開環重合させて得られる重合体を使用することにより達成。
【選択図】なし
Description
東京女子医科大学工学研究施設編、21世紀を開く先端医療、第139〜140頁、株式会社ニュートンプレス(1999) 川瀬雅也、八木清仁、生物工学、第80巻(5)、189(2002)
L−ラクチドモノマー10g、触媒としてのテトラブトキシチタン0.03g、オクチルアルコール0.001gを100ml容量のアンプルに添加し、更に溶媒として塩化メチレン50mlを添加し、室温で完全に溶解させた。その後、減圧下で溶媒の塩化メチレンを除去し、均一な混合物を得た。窒素封入後、アンプルを密封し、140℃で4時間、加熱混合し、重合を行った。加熱停止後、放冷した。室温まで冷却後、反応物をテトラヒドロフラン100mlに溶解させて、溶解液を冷メタノール中に滴下して、無色の沈殿物を得た。これを減圧乾燥して、再度テトラヒドロフラン100mlに溶解させ、溶解液を冷メタノール中に滴下して精製を行った。これを減圧乾燥し、ポリマーを得た。得られたポリマーの収量は、5.82gで、収率は、58.2%であった。更に、このものについて、残存チタン量をIPC(原子吸光分析)で測定したところ、残存チタン量は、114ppmであった。
(測定条件)
使用機種:東ソー(株)製SC−8010システム
カラム:Shodex K−800D+K−805L×2本
溶媒:CHCl3
温度:カラム恒温槽40℃
濃度:約0.1wt/vol%
流速:1.0ml/分
標準試料:ポリスチレンスタンダード
検出器:示差屈折計(R1)
測定結果は、Mwが、2.08×104、Mnが1.80×104で、Mw/Mnが1.15であった。
L−ラクチドモノマーに代えてε−カプロラクタム10gを使用した以外は、実施例1と同じ条件下で重合を行った。得られたポリマーの収量は、7.45g、収率は、74.5%であった。残存チタン量についても同様に測定したところ、63.5ppmであった。分子量についても、同様に測定したところ、Mwが、1.29×105、Mnが5.16×104で、Mw/Mnが2.50であった。
同様にして、乳酸とε−カプロラクタムとをモル比で84%:16%を含む乳酸−カプロラクトン共重合体が得られるような量を用い、触媒として塩化鉄(II)を使用して、乳酸−カプロラクトン共重合体Aを得た。このもののMwは、18.4×104、Mnが11.5×104で、残存鉄の量は200ppmであった。また、乳酸とε−カプロラクタムとをモル比で60%:40%を含む乳酸−カプロラクトン共重合体が得られるような量を用い、触媒として塩化亜鉛ジエチルエーテル錯体を使用して、乳酸−カプロラクトン共重合体Bを得た。このもののMwは、23.4×104、Mnが15.0×104で、残存亜鉛の量は100ppmであった。
触媒としてオクチルスズ0.03gを使用した以外は、実施例1と同じ条件下で重合を行った。得られたポリマーの収量は、6.32g、収率は、63.2%であった。残存スズ量について同様に測定したところ、529ppmであった。分子量についても、同様に測定したところ、Mwが、2.85×105、Mnが1.66×104で、Mw/Mnが1.72であった。
L−ラクチドモノマーに代えてε−カプロラクタムを10g使用した以外は、比較例1と同じ条件下で重合を行った。得られたポリマーの収量は、8.28g、収率は、82.8%であった。残存スズ量について同様に測定したところ、862ppmであった。分子量についても、同様に測定したところ、Mwが、1.44×105、Mnが6.93×104で、Mw/Mnが2.07であった。
(軟骨細胞の増殖及び軟骨細胞の分化に対する影響についての評価)
実施例1で得られたポリ乳酸、同様にして製造した上記乳酸−カプロラクトン共重合体A、及び乳酸−カプロラクトン共重合体B、比較例1で得られたポリ乳酸、並びに金属を利用しないプロセスで合成された市販のポリ乳酸(商品名:ラクテイ2000;島津製作所製)を用いて、ヒト軟骨細胞の分化・増殖に及ぼす影響を評価した。
各ポリマーをジメチルスルホキシドに溶解させポリマー溶液を得た。各ヒト軟骨細胞培養系に、ポリマー濃度で50μg/mlの濃度となるように各ポリマー溶液を添加し、かくして調製した試料を炭酸ガスインキュベーター中で、37℃で4週間培養した。
培養終了後、軟骨細胞の増殖は、クリスタルバイオレットで、また、軟骨細胞の分化は、アルシアンブルーで、それぞれ試料を染色し、得られた染色見本を用いて、増殖・分化の状態を評価した。なお、ポリ乳酸溶液を添加していない試料の軟骨細胞の増殖及び分化状況を100として、相対的評価により行った。評価結果は、以下の表1に示す。
Claims (11)
- 生体吸収性であって、生体細胞の増殖・分化の機能促進作用を示すに充分な量の生体細胞の増殖・分化の機能促進作用を示す金属元素及び/又は同金属元素の化合物を含む、合成重合体からなる材料。
- 前記合成重合体が、乳酸類、グリコール酸類、ヒドロキシアルカン酸、及びε−カプロラクトンから選ばれる少なくとも1種以上の成分から得られる(共)重合体であることを特徴とする請求項1に記載の材料。
- 前記金属元素及び/又は同金属元素の化合物が、チタン、ジルコニウム、ハフニウム、ニオブ、タンタル、亜鉛及び鉄から選ばれる少なくとも1種以上の金属元素、及びこの金属元素の化合物であることを特徴とする請求項1又は2に記載の材料。
- 前記金属元素の化合物が、金属元素の塩化物、金属元素のアルコキシド化合物、金属元素のカルボン酸化合物及びその塩化合物、及び金属元素のアセチルアセトン錯体から選ばれる成分であることを特徴とする請求項3に記載の材料。
- 前記金属元素及び/又は同金属元素の化合物の含有量は、前記材料100質量部に対し、0.000001〜2質量部であることを特徴とする請求項1〜4のいずれか1項に記載の材料。
- 請求項1〜5の何れか1項に記載の材料を使用した細胞・組織培養用基材。
- 請求項1〜5の何れか1項に記載の材料を使用した埋植用医療器具。
- 請求項1〜5の何れか1項に記載の材料の製造方法であり、
前記金属元素及び/又は同金属元素の化合物の存在下で、乳酸類、グリコール酸類、ヒドロキシアルカン酸、及びε−カプロラクトンから選ばれる少なくとも1種の成分を重合させることを特徴とする合成重合体からなる材料の製造方法。 - 前記金属元素及び/又は同金属元素の化合物の添加量が、前記重合体からなる材料100質量部に対し、0.000001〜2質量部であることを特徴とする請求項8に記載の材料の製造方法。
- 前記金属元素及び/又は同金属元素の化合物が、チタン、ジルコニウム、ハフニウム、ニオブ、タンタル、亜鉛及び鉄から選ばれる少なくとも1種の金属元素及び/又は同金属元素の化合物であることを特徴とする請求項8又は9に記載の材料の製造方法。
- 前記金属元素の化合物が、金属元素の塩化物、金属元素のアルコキシド化合物、金属元素のカルボン酸化合物及びその塩化合物、及び金属元素のアセチルアセトン錯体から選ばれる成分であることを特徴とする請求項10に記載の材料の製造方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004167632A JP4674331B2 (ja) | 2004-06-04 | 2004-06-04 | 細胞・組織培養用基材、及び宿主内埋め込み用構造体 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004167632A JP4674331B2 (ja) | 2004-06-04 | 2004-06-04 | 細胞・組織培養用基材、及び宿主内埋め込み用構造体 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005342336A true JP2005342336A (ja) | 2005-12-15 |
JP4674331B2 JP4674331B2 (ja) | 2011-04-20 |
Family
ID=35495224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004167632A Expired - Lifetime JP4674331B2 (ja) | 2004-06-04 | 2004-06-04 | 細胞・組織培養用基材、及び宿主内埋め込み用構造体 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4674331B2 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006305348A (ja) * | 2003-06-13 | 2006-11-09 | Tyco Healthcare Group Lp | 所定の吸収速度を有する外科用固定具 |
JP2008063420A (ja) * | 2006-09-06 | 2008-03-21 | Teijin Ltd | ポリ乳酸およびその製造方法 |
JPWO2020262609A1 (ja) * | 2019-06-27 | 2020-12-30 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60185562A (ja) * | 1976-01-12 | 1985-09-21 | エチコン・インコ−ポレ−テツド | 外科用補綴 |
JPS62212423A (ja) * | 1986-03-12 | 1987-09-18 | Fuso Kagaku Kogyo Kk | ヒドロキシポリカルボン酸エステルの重合体または共重合体の製造法 |
JPH083292A (ja) * | 1994-06-21 | 1996-01-09 | Mitsubishi Chem Corp | 脂肪族ポリエステルの製造方法 |
-
2004
- 2004-06-04 JP JP2004167632A patent/JP4674331B2/ja not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60185562A (ja) * | 1976-01-12 | 1985-09-21 | エチコン・インコ−ポレ−テツド | 外科用補綴 |
JPS62212423A (ja) * | 1986-03-12 | 1987-09-18 | Fuso Kagaku Kogyo Kk | ヒドロキシポリカルボン酸エステルの重合体または共重合体の製造法 |
JPH083292A (ja) * | 1994-06-21 | 1996-01-09 | Mitsubishi Chem Corp | 脂肪族ポリエステルの製造方法 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006305348A (ja) * | 2003-06-13 | 2006-11-09 | Tyco Healthcare Group Lp | 所定の吸収速度を有する外科用固定具 |
JP2008063420A (ja) * | 2006-09-06 | 2008-03-21 | Teijin Ltd | ポリ乳酸およびその製造方法 |
JPWO2020262609A1 (ja) * | 2019-06-27 | 2020-12-30 | ||
JP7414067B2 (ja) | 2019-06-27 | 2024-01-16 | 株式会社レゾナック | 細胞足場材、細胞培養支持体、及び細胞の培養方法 |
Also Published As
Publication number | Publication date |
---|---|
JP4674331B2 (ja) | 2011-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Singhvi et al. | Polylactic acid: synthesis and biomedical applications | |
Martin et al. | Medical applications of poly-4-hydroxybutyrate: a strong flexible absorbable biomaterial | |
Pêgo et al. | Biodegradable elastomeric scaffolds for soft tissue engineering | |
Misra et al. | Polyhydroxyalkanoate (PHA)/inorganic phase composites for tissue engineering applications | |
JP4376455B2 (ja) | 制御された分解速度を有するポリヒドロキシアルカノエート組成物 | |
Ying et al. | Scaffolds from electrospun polyhydroxyalkanoate copolymers: fabrication, characterization, bioabsorption and tissue response | |
Albertsson et al. | Recent developments in ring opening polymerization of lactones for biomedical applications | |
Pego et al. | In vivo behavior of poly (1, 3‐trimethylene carbonate) and copolymers of 1, 3‐trimethylene carbonate with D, L‐lactide or ϵ‐caprolactone: Degradation and tissue response | |
Valappil et al. | Biomedical applications of polyhydroxyalkanoates, an overview of animal testing and in vivo responses | |
Davison et al. | Degradation of biomaterials | |
JP5219030B2 (ja) | 刺激応答性分解ゲル | |
JP2002539854A (ja) | ポリヒドロキシアルカノエートポリマーの医療デバイスおよび医療適用 | |
Bat et al. | Trimethylene carbonate and ϵ-caprolactone based (co) polymer networks: mechanical properties and enzymatic degradation | |
Chłopek et al. | The influence of the environment on the degradation of polylactides and their composites | |
Benatti et al. | Bioreabsorbable polymers for tissue engineering: PLA, PGA, and their copolymers | |
Rai et al. | The homopolymer poly (3‐hydroxyoctanoate) as a matrix material for soft tissue engineering | |
Adamus et al. | Degradation of nerve guidance channels based on a poly (L-lactic acid) poly (trimethylene carbonate) biomaterial | |
Yuan et al. | Thermosensitive vancomycin@ PLGA-PEG-PLGA/HA hydrogel as an all-in-one treatment for osteomyelitis | |
Barbanti et al. | Effect of salt leaching on PCL and PLGA (50/50) resorbable scaffolds | |
Wan et al. | Bulk erosion degradation mechanism for poly (1, 8-octanediol-co-citrate) elastomer: an in vivo and in vitro investigation | |
Tang et al. | Tailoring polylactide degradation: copolymerization of a carbohydrate lactone and S, S-lactide | |
Messias et al. | Synthesis, Characterization, and Osteoblastic Cell Culture of Poly (L‐co‐D, L‐lactide‐co‐trimethylene carbonate) Scaffolds | |
Kivijärvi et al. | Hybrid material based on hyaluronan hydrogels and poly (l-lactide-co-1, 3-trimethylene carbonate) scaffolds toward a cell-instructive microenvironment with long-term in vivo degradability | |
JP4674331B2 (ja) | 細胞・組織培養用基材、及び宿主内埋め込み用構造体 | |
Hege et al. | Biopolymer systems in soft tissue engineering: cell compatibility and effect studies including material, catalyst, and surface properties |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061214 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20070913 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100629 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100827 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101019 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101029 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20101130 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101228 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140204 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4674331 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313115 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |